<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974389</url>
  </required_header>
  <id_info>
    <org_study_id>OSAKA-TRICC0901</org_study_id>
    <secondary_id>CDR0000649021</secondary_id>
    <nct_id>NCT00974389</nct_id>
  </id_info>
  <brief_title>S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable or Recurrent Colorectal Cancer After Failure of Prior Chemotherapy, Including Irinotecan and Oxaliplatin Regimens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as S-1, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal&#xD;
      antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the&#xD;
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or&#xD;
      carry tumor-killing substances to them. Giving S-1 together with bevacizumab may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving S-1 together with bevacizumab works&#xD;
      as third-line therapy in treating patients with colorectal cancer that is recurrent or that&#xD;
      cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate giving S-1 with bevacizumab to see how well it works as third-line therapy&#xD;
           in KRAS-mutation patients with unresectable or recurrent colorectal cancer.&#xD;
&#xD;
      OUTLINE: Patients receive oral S-1 twice daily on days 1-28 and bevacizumab IV on days 1, 15,&#xD;
      and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-control rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-gimeracil-oteracil potassium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed colorectal carcinoma&#xD;
&#xD;
               -  Inoperable, locally advanced, or metastatic disease&#xD;
&#xD;
               -  KRAS-mutated&#xD;
&#xD;
          -  Concurrently receiving treatment containing irinotecan and oxaliplatin regimens for&#xD;
             unresectable or recurrent colorectal cancer&#xD;
&#xD;
          -  Measurable disease according to RECIST&#xD;
&#xD;
          -  No moderate or severe ascites or pleural effusion requiring treatment&#xD;
&#xD;
          -  No metastasis to the CNS&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  White blood cell count &gt; 3,500/mm³ but &lt; 12,000/mm³&#xD;
&#xD;
          -  Neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 100 U/L (&lt; 200 U/L in patients with liver metastasis)&#xD;
&#xD;
          -  Serum creatinine &lt; 1.2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt; 1+&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Able to take capsules orally&#xD;
&#xD;
          -  No active second cancer&#xD;
&#xD;
          -  No active infections (e.g., patients with pyrexia of ≥ 38°C)&#xD;
&#xD;
          -  No serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart&#xD;
             failure, renal failure, hepatic failure, poorly controlled diabetes, or hypertension)&#xD;
&#xD;
          -  No electrocardiographic abnormalities with cardiac disorder that would clinically&#xD;
             preclude the execution of the study as judged by the investigator&#xD;
&#xD;
          -  No serious drug hypersensitivity or a history of drug allergy&#xD;
&#xD;
          -  No thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism&#xD;
&#xD;
          -  No history or evidence of inherited bleeding diathesis or coagulopathy with the risk&#xD;
             of bleeding&#xD;
&#xD;
          -  No clinically significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  No severe mental disorder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent low-dose aspirin therapy (&lt; 325 mg/day) allowed&#xD;
&#xD;
          -  More than 4 weeks since prior major surgical procedure or open biopsy&#xD;
&#xD;
          -  No prior therapy radiotherapy&#xD;
&#xD;
          -  No prior therapy with S-1&#xD;
&#xD;
          -  No prior chemotherapy include irinotecan and oxaliplatin as first- or second-line&#xD;
             treatment.&#xD;
&#xD;
          -  No concurrent continuous treatment with steroids&#xD;
&#xD;
          -  No concurrent treatment with flucytosine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroya Takiuchi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Medical College</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Medical College</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroya Takiuchi, MD, PhD</last_name>
      <phone>81-72-683-1221</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

